. Author manuscript; available in PMC: 2022 Dec 1.

Published in final edited form as: Arthritis Rheumatol. 2021 Nov 2;73(12):2166–2178. doi: 10.1002/art.41906

Table 1:

Approved Jakinibs and their current indications

Drug	Target	Indication
Tofacitinib	JAK1/JAK2/JAK3	RA, PsA, UC, polyarticular course JIA
Baricitinib	JAK1/JAK2	RA, Covid-19 (EUA)
Upadacitinib	JAK1	RA
Filgotinib	JAK1	RA (approved in EU, Japan)
Peficitinib	Multiple JAKs	RA (approved in Japan, Korea)
Ruxolitinib	JAK1/JAK2	MPN, acute GvHD
Fedratinib	JAK2/FLT3/RET/BRD4	MPN
Delgocitinib (Topical)	Multiple JAKs	AD (approved in Japan)
Oclacitinib	Multiple JAKs	AD (dogs)

RA, rheumatoid arthritis; PsA, psoriatic arthritis; UC, ulcerative colitis; JIA, juvenile idiopathic arthritis; MPN, myeloproliferative neoplasms; GvHD, graft-versus-host disease; AD, atopic dermatitis